Clinical trials: Treatment Resistant Depressive Disorder
Depression
Mifepristone in Refractory Depression
The purpose of the study is to examine the effectiveness of mifepristone treatment in patients with refractory depression. Refractory depression is defined as clinical depression that is unimproved after treatment with at least 2…
- Trial name
- NCT00186056
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Stanford University
Treatment Resistant Depression
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
- Trial name
- NCT04739865
- Testing
- Psilocybin
- Where
- 2 sites in United States, Ireland
- Volunteers
- 19 people
- Sponsor
- COMPASS Pathways
Treatment Resistant Depression
Personalized Therapeutic Neuromodulation for Anhedonic Depression
This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).
- Trial name
- NCT05144789
- Testing
- Active TBS-DLPFC, Active TBS-DMPFC
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Stanford University
Treatment Resistant Depressive Disorder
Ketamine for Treatment Resistant Late-Life Depression
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine…
- Trial name
- NCT02556606
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Treatment- Resistant Bipolar Disorder, Bipolar Disorder
Nitrous TRD Bipolar Depression
Investigators will study approximately 64 patients with Treatment-Resistant Bipolar Depressive Disorder, defined as a failure of at least 1 antidepressants in the current depressive episode and 2 lifetime medication failures.
- Conditions
- Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder
- Trial name
- NCT02757521
- Testing
- Nitrous Oxide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Depression, Suicide
Ketamine for Depression and Suicide Risk
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S.
- Trial name
- Ketamine (NCT02094898)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Treatment Resistant Depression
Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms
This study will be an open-label 6-week (30 session) trial of active repetitive transcranial magnetic stimulation (rTMS) using a fixed frequency (10 Hz) but varying stimulation intensities using a 3+3 study design for safety and…
- Trial name
- NCT02611206
- Testing
- Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Major Depressive Disorder
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated.
- Trial name
- NCT01582945
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression, Major Depressive Disorder
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT02522377
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression (Pilot)
Treatment resistant depression (TRD) is a major public health problem. Current therapeutic options for this patient population remain limited.
- Trial name
- NCT01179009
- Testing
- Ketamine, Clonidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
Neuroimaging in Patients Undergoing TMS for Depression
The goal of this project is to guide rTMS using functional magnetic resonance imaging (fMRI) in individuals with depression who did not respond to standard TMS treatment to evaluate whether targeted TMS using individualized…
- Trial name
- NIPUTFD (NCT02974296)
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- New York State Psychiatric Institute
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Bipolar Disorder
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression
We hope to learn whether this stimulation of neurons in the front part of the brain may relieve depression.
- Trial name
- NCT00186485
- Testing
- MagStim
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
Treatment Resistant Depression
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled.
- Trial name
- ENLIGHTEN (NCT05113771)
- Testing
- Liafensine
- Where
- 45 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Denovo Biopharma LLC
Treatment Resistant Depression (TRD)
Maintenance TMS in Treatment Resistant Depression
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use.
- Trial name
- NCT06682299
- Testing
- Transmagnetic Stimulation, Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Austin Messner
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the safety and efficacy of low field magnetic stimulation (LFMS) for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID (NCT01654796)
- Testing
- Low Field Magnetic Stimulation (LFMS)
- Where
- 6 sites in United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
Abilify as an Adjunctive Treatment for Refractory Depression
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not…
- Trial name
- NCT00220636
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center